The results of the clinico-laboratory and epidemiological study of a newly developed live measles vaccine obtained from strain Moscow-5, genetically homogeneous and cloned from strain JI-16, are presented. The data indicate that the vaccine obtained from strain Moscow-5 is safe and possesses low reactogenicity and high immunological potency, thus meeting all requirements for vaccinal preparations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Measles, mumps and rubella vaccination coverage in capitals and interior region municipalities of Northeast Brazil: a household survey in a cohort of children born in 2017 and 2018.
Epidemiol Serv Saude
December 2024
Universidade de Brasília, Brasília, DF, Brazil.
Objective: To analyze measles, mumps, and rubella vaccination coverage among children up to 24 months old and factors associated with non-vaccination in a 2017-2018 live birth cohort, in state capitals and large interior region cities in Northeast Brazil.
Methods: Population-based survey analyzing vaccination coverage and sociodemographic factors through logistic regression.
Results: For 12,137 children, vaccination coverage was 79.
Induction of tissue resident memory T cells by measles vaccine vector.
Hum Vaccin Immunother
December 2024
Interactions hôte-pathogène, Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France.
Measles live attenuated vaccine (MV) induces strong humoral and cellular systemic memory responses allowing the successful control of measles since decades. MV has also been adapted into a promising vaccine platform with several vaccine candidates in clinical development. To understand and document the tissue-scaled memory response induced by MV, we explored the specific induction and persistence of resident memory T cells (Trm) in the lungs and the liver, two critical targeted tissues for vaccine development against several diseases.
View Article and Find Full Text PDFLive-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision.
Mult Scler
December 2024
Department of Neurology, Fleni, Buenos Aires, Argentina.
Live-attenuated vaccines provide robust immunity against diseases like tuberculosis, measles, mumps, rubella, polio, yellow fever, dengue, typhoid fever, and varicella, with just one or a few doses. However, concerns arise regarding potential pathogen reversion to virulence, which is particularly risky for immunocompromised individuals, contraindicating their administration in multiple sclerosis (MS) patients under modified disease treatments due to the possibility of triggering infections, or stimulating the immune system, precipitating new exacerbations. On the contrary, these vaccines offer enduring immunity that is crucial for protecting MS patients from endemic infectious diseases, leading to severe complications if contracted.
View Article and Find Full Text PDF[Microplanning as a tool to strengthen the National Immunization Program in BrazilLa microplanificación como herramienta para fortalecer el Programa Nacional de Inmunizaciones en Brasil].
Rev Panam Salud Publica
December 2024
Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente Departamento de Doenças Imunopreveníveis Brasília (DF) Brasil Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Departamento de Doenças Imunopreveníveis, Brasília (DF), Brasil.
Objective: To measure the variation in number of doses, vaccination coverage (VC) of administered vaccines, and number of municipalities that achieved the VC target in Brazil with the implementation of microplanning for high-quality vaccination activities (HQVA) and decentralized multivaccination actions.
Methods: This quasi-experimental study used data from the National Live Birth Information System, the National Immunization Program Information System, and the National Health Data Network. The number of doses of hepatitis A (HA), meningococcal conjugate-C, oral poliomyelitis, 10-valent pneumococcal, diphtheria-tetanus-pertussis (DTP), and measles-mumps-rubella (MMR) vaccines administered to children under 2 years of age in 2022 (pre-microplanning) and 2023 (post-microplanning) was estimated.
Live Attenuated Vaccine Administration in Children Treated With Methotrexate or Dupilumab.
Pediatr Dermatol
December 2024
Department of Pediatrics and Dermatology, SSM Health and Saint Louis University, St. Louis, Missouri, USA.
Background And Objectives: A wholesale recommendation against use of live virus vaccines in patients treated with any medication classified as an immunosuppressant has been based on global theoretical concerns rather than clinical outcomes for specific drugs.
Methods: A retrospective search of electronic medical records identified patients seen by the Allergy and/or Dermatology services between 2017 and 2023 at a pediatric tertiary center who received a live attenuated vaccine during the 6 week interval prior to the first prescription for methotrexate or dupilumab until 6 weeks after the last prescription for either medication. Individual charts of identified patients were manually reviewed for evidence of adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!